Frazier Life Sciences Management, L.P. Portfolio Holdings

Frazier Life Sciences Management, L.P.

  • $1.67 Billion
  • Q4 2024

Frazier Life Sciences Management, L.P. has filed its 13F form on February 14, 2025 for Q4 2024 where it was disclosed a total value porftolio of $1.67 Billion distributed in 50 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Mirum Pharmaceuticals, Inc. with a value of $272M, Verona Pharma PLC with a value of $157M, Krystal Biotech, Inc. with a value of $124M, Arcutis Biotherapeutics, Inc. with a value of $122M, and Rhythm Pharmaceuticals, Inc. with a value of $105M.

Examining the 13F form we can see an decrease of $190M in the current position value, from $1.86B to 1.67B.

Frazier Life Sciences Management, L.P. is based out at Menlo Park, CA

Below you can find more details about Frazier Life Sciences Management, L.P. portfolio as well as his latest detailed transactions.

Portfolio value $1.67 Billion
Healthcare: $1.67 Billion

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
$1.95B
$272 Million 16.29% of portfolio
6,570,392
Q3 2024 Added 1.15%
$3.91B
$157 Million 9.42% of portfolio
3,383,950
Q3 2024 Added 2.1%
$4.69B
$124 Million 7.41% of portfolio
788,460
Q4 2024 Reduced 20.23%
$808M
$122 Million 7.34% of portfolio
8,785,284
Q1 2024 Added 0.24%
$3.21B
$105 Million 6.27% of portfolio
1,869,808
Q4 2024 Reduced 22.64%
$5.46B
$104 Million 6.25% of portfolio
3,800,457
Q4 2024 Added 1.06%
$1.3B
$87.9 Million 5.27% of portfolio
1,587,527
Q2 2024 Reduced 11.19%
$217M
$82.1 Million 4.92% of portfolio
10,109,279
Q2 2023 Added 20.25%
$178M
$48.7 Million 2.92% of portfolio
19,391,687
Q3 2024 Added 19.58%
$285M
$45.4 Million 2.72% of portfolio
10,664,774
Q4 2024 Added 44.49%
$4.89B
$44.2 Million 2.65% of portfolio
539,405
Q4 2024 Reduced 38.66%
$3.71B
$43.6 Million 2.62% of portfolio
997,455
Q3 2023 Added 16.73%
$262M
$41.4 Million 2.48% of portfolio
4,887,867
Q4 2024 Added 32.54%
$1.85B
$35.2 Million 2.11% of portfolio
1,069,754
Q4 2024 Added 2.45%
$1.71B
$33.9 Million 2.04% of portfolio
1,271,245
Q4 2024 Reduced 55.13%
$296M
$31.4 Million 1.88% of portfolio
3,888,238
Q4 2024 Reduced 6.15%
$307M
$26.6 Million 1.59% of portfolio
8,660,379
Q4 2024 Added 6.17%
$62.5M
$21.7 Million 1.3% of portfolio
10,617,062
Q2 2024 Added 8.54%
$823M
$18.6 Million 1.11% of portfolio
1,479,025
Q4 2024 Reduced 0.44%
$8.63B
$18.4 Million 1.1% of portfolio
133,333
Q3 2024 New
$359M
$17.8 Million 1.07% of portfolio
5,097,779
Q3 2024 Added 15.82%
$5.83B
$17.3 Million 1.04% of portfolio
601,129
Q4 2024 Added 4.34%
$2.19B
$15.7 Million 0.94% of portfolio
373,100
Q2 2024 Reduced 50.02%
$351M
$15.3 Million 0.92% of portfolio
2,147,911
Q4 2024 Added 58.55%
$147M
$14.8 Million 0.89% of portfolio
1,120,803
Q4 2024 New
$280M
$12.1 Million 0.72% of portfolio
1,953,547
Q4 2024 Added 3.22%
$177M
$10.9 Million 0.65% of portfolio
4,623,324
Q1 2024 Added 23.39%
$177M
$10.3 Million 0.62% of portfolio
3,175,665
Q4 2024 Added 5.48%
$3.28B
$8.63 Million 0.52% of portfolio
470,338
Q1 2024 Reduced 35.65%
$898M
$8.74 Million 0.52% of portfolio
689,655
Q3 2024 New
$179M
$7.9 Million 0.47% of portfolio
1,148,591
Q1 2024 Added 30.35%
$509M
$7.67 Million 0.46% of portfolio
1,000,000
Q1 2024 Reduced 50.0%
$532M
$7.31 Million 0.44% of portfolio
936,576
Q1 2024 Reduced 53.06%
$325M
$6.11 Million 0.37% of portfolio
2,867,750
Q1 2024 New
$977M
$5.47 Million 0.33% of portfolio
285,331
Q2 2022 Added 5.55%
$60.4M
$4.81 Million 0.29% of portfolio
1,176,735
Q4 2024 New
$14.9M
$3.48 Million 0.21% of portfolio
5,993,579
Q3 2024 Added 102.58%
$1.31B
$3.21 Million 0.19% of portfolio
108,762
Q2 2024 New
Lexeo Therapeutics Inc
-
$0 0.0% of portfolio
-
Q4 2024 Reduced 23.61%
-
$0 0.0% of portfolio
-
Q4 2024 Added 23.81%
-
$0 0.0% of portfolio
-
Q4 2022 New
Cg Oncology Inc
-
$0 0.0% of portfolio
-
Q1 2024 New
Oruka Therapeutics Inc
-
$0 0.0% of portfolio
-
Q4 2024 Added 22.21%
Palvella Therapeutics Inc Ne
-
$0 0.0% of portfolio
-
Q4 2024 New
Anaptysbio Inc
-
$0 0.0% of portfolio
-
Q4 2024 Reduced 28.76%
Disc Medicine Inc
-
$0 0.0% of portfolio
-
Q2 2024 Added 123.55%
Adverum Biotechnologies Inc
-
$0 0.0% of portfolio
-
Q2 2024 New
Mbx Biosciences Inc
-
$0 0.0% of portfolio
-
Q3 2024 New
Soleno Therapeutics Inc
-
$0 0.0% of portfolio
-
Q4 2024 Reduced 20.16%

Summary

  • Portfolio
  • No. of Stocks 50
  • Current Value $1.67 Billion
  • Prior Value $1.86 Billion
  • Filing
  • Period Q4 2024
  • Filing Date February 14, 2025
  • Form Type 13F-HR
  • Activity in Q4 2024
  • New Purchases 3 stocks
  • Additional Purchases 12 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 9 stocks
Track This Portfolio

Track Frazier Life Sciences Management, L.P. Portfolio

Follow Frazier Life Sciences Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Frazier Life Sciences Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Frazier Life Sciences Management, L.P. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email